For more information on WelChol, call 877-4-DSPROD (877-431-7763), or go to the WelChol web site at http://www.WelChol.com.
About Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd., Japan's second largest pharmaceutical company and a global leader in pharmaceutical innovation since 1899. The company is dedicated to the discovery, development and commercialization of innovative medicines that improve the lives of patients throughout the world.
The primary focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes, and acute coronary syndrome. The company is also pursuing the discovery of new medicines in the areas of glucose metabolic disorders, infectious diseases, cancer, bone and joint diseases, and immune disorders.
For more information, please visit http://www.dsus.com.
Trademarks not owned by Daiichi Sankyo, Inc., are the property of their respective owners.
About the Survey
This survey was conducted by telephone within the United States by
Harris Interactive on behalf of Daiichi Sankyo between January 17 and
February 5, 2007 among a nationally representative sample of 400 U.S.
adults ages 20 and older who have been diagnosed with high cholesterol and
are doing something to manage it. Management includes: exercising
regularly, changing diet, taking prescription medication, taking
over-the-counter medication or eating cholesterol lowering food products.
|SOURCE Daiichi Sankyo, Inc.|
Copyright©2007 PR Newswire.
All rights reserved